News
Videos
Conferences
Events
Resources
Subscribe

|Videos|August 18, 2022

Historic and Current Treatment Options for mUM

Author(s)Sunandana Chandra, MD, MS

An expert provides an overview of the historical and currently available treatment options in metastatic uveal melanoma (mUM), including the bispecific T-cell receptor immunotherapy tebentafusp (“teh-BEN-tah-fuhsp”).

Episodes in this series

EP. 1 How Uveal Melanoma Differs from Cutaneous Melanoma

EP. 1 How Uveal Melanoma Differs from Cutaneous Melanoma

EP. 2 Common Symptoms of Uveal Melanoma and the Typical Diagnostic Journey of the Patient

EP. 2 Common Symptoms of Uveal Melanoma and the Typical Diagnostic Journey of the Patient

EP. 3 Historic and Current Treatment Options for mUM

EP. 3 Historic and Current Treatment Options for mUM

EP. 4 Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM

EP. 4 Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM

EP. 5 Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM

EP. 5 Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM

EP. 6 An Expert’s Experience in Prescribing Tebentafusp and Other Therapies for mUM and a Commentary on Patient Education and Resources

EP. 6 An Expert’s Experience in Prescribing Tebentafusp and Other Therapies for mUM and a Commentary on Patient Education and Resources

EP. 7 Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy

EP. 7 Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy

EP. 8 Advice for Patients Living with Metastatic Uveal Melanoma

EP. 8 Advice for Patients Living with Metastatic Uveal Melanoma

Newsletter

Stay up to date on cancer updates, research and education

Related Content

The Future of CLL Care: Medical Breakthroughs and Patient-Physician Collaboration

September 20th 2024

Living Well With CLL: Nutrition, Exercise, and Lifestyle Tips From Patients and Doctors

September 20th 2024

Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs

September 13th 2024

CLL Treatment and Quality of Life: Patient Empowerment and Shared Decision-making

September 13th 2024

LL Treatment Roadmap: Navigating First-Line Options With Your Doctor

September 6th 2024

Trending on CURE

FDA Approves Breyanzi in Relapsed/Refractory Marginal Zone Lymphoma

Every FDA Oncology Approval From November 2025

11 Years Living With Stage 4 Cancer Inspires Gratitude and Reflection

What Patients Should Know About EGFR Mutated Lung Cancer Treatment

What Patients With AML Need to Know About Azacitidine and Venclexta

© 2025 MJH Life Sciences^®

All rights reserved.